Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Pinato

Showing results (111-120 of 238) with videos related to

Pageof 24
Sort By:
Cell Reports. Medicine|June 22, 2023
Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancerHaonan Lu, Hantao Lou, Georg Wengert, et al.
British Journal of Cancer|October 19, 2020
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort studySaur Hajiev, Elias Allara, Leila Motedayеn Aval, et al.
JAMA Oncology|September 2, 2021
COVID-19 and Cancer: A Review of the Registry-Based Pandemic ResponseAakash Desai, Turab J Mohammed, Narjust Duma, et al.
Frontiers in Oncology|June 16, 2023
Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysisShobana Anpalakhan, Prerana Huddar, Roya Behrouzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancerSarah Blagden, Aurelius Omlin, Aurelius Olmin, et al.
Journal of Hepatology|September 29, 2016
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinomaDavid J Pinato, Rohini Sharma, Elias Allara, et al.
Gut|September 30, 2024
Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinomaHenrike Salié, Lara Wischer, Antonio D'Alessio, et al.
JAMA Oncology|September 13, 2019
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With CancerDavid J Pinato, Sarah Howlett, Diego Ottaviani, et al.
European Radiology|July 27, 2023
Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC managementBachir Taouli, Ahmed Ba-Ssalamah, Julius Chapiro, et al.
Cancer Research Communications|May 13, 2026
Early ctDNA dynamics predict response to mosperafenib in BRAF V600-mutant metastatic colorectal cancerMartha Liliana Serrano-Serrano, Christina Godfried Sie, Oliver Bechter, et al.
Pageof 24

Showing results (111-120 of 238) with videos related to

Sort By:
Pageof 24
Cell Reports. Medicine|June 22, 2023
Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancerHaonan Lu, Hantao Lou, Georg Wengert, et al.
British Journal of Cancer|October 19, 2020
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort studySaur Hajiev, Elias Allara, Leila Motedayеn Aval, et al.
JAMA Oncology|September 2, 2021
COVID-19 and Cancer: A Review of the Registry-Based Pandemic ResponseAakash Desai, Turab J Mohammed, Narjust Duma, et al.
Frontiers in Oncology|June 16, 2023
Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysisShobana Anpalakhan, Prerana Huddar, Roya Behrouzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancerSarah Blagden, Aurelius Omlin, Aurelius Olmin, et al.
Journal of Hepatology|September 29, 2016
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinomaDavid J Pinato, Rohini Sharma, Elias Allara, et al.
Gut|September 30, 2024
Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinomaHenrike Salié, Lara Wischer, Antonio D'Alessio, et al.
JAMA Oncology|September 13, 2019
Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With CancerDavid J Pinato, Sarah Howlett, Diego Ottaviani, et al.
European Radiology|July 27, 2023
Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC managementBachir Taouli, Ahmed Ba-Ssalamah, Julius Chapiro, et al.
Cancer Research Communications|May 13, 2026
Early ctDNA dynamics predict response to mosperafenib in BRAF V600-mutant metastatic colorectal cancerMartha Liliana Serrano-Serrano, Christina Godfried Sie, Oliver Bechter, et al.
Pageof 24